Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers
The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of tradition...
Saved in:
| Published in | Oncology reviews Vol. 19; p. 1581856 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
14.04.2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of traditional CAR T cell therapy in gastrointestinal cancers faces numerous challenges, including the suppressive tumor microenvironment and limitations in anti-tumor efficacy. The application of engineered bacteria offers a novel strategy to enhance CAR T cell therapy by modulating the tumor microenvironment and boosting immune responses, potentially leading to improved therapeutic outcomes. This review synthesizes the current research advancements related to engineered bacteria-assisted CAR T cell therapy in gastrointestinal cancers, exploring its underlying mechanisms, clinical applications, and future developmental directions. |
|---|---|
| AbstractList | The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of traditional CAR T cell therapy in gastrointestinal cancers faces numerous challenges, including the suppressive tumor microenvironment and limitations in anti-tumor efficacy. The application of engineered bacteria offers a novel strategy to enhance CAR T cell therapy by modulating the tumor microenvironment and boosting immune responses, potentially leading to improved therapeutic outcomes. This review synthesizes the current research advancements related to engineered bacteria-assisted CAR T cell therapy in gastrointestinal cancers, exploring its underlying mechanisms, clinical applications, and future developmental directions. The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of traditional CAR T cell therapy in gastrointestinal cancers faces numerous challenges, including the suppressive tumor microenvironment and limitations in anti-tumor efficacy. The application of engineered bacteria offers a novel strategy to enhance CAR T cell therapy by modulating the tumor microenvironment and boosting immune responses, potentially leading to improved therapeutic outcomes. This review synthesizes the current research advancements related to engineered bacteria-assisted CAR T cell therapy in gastrointestinal cancers, exploring its underlying mechanisms, clinical applications, and future developmental directions.The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of traditional CAR T cell therapy in gastrointestinal cancers faces numerous challenges, including the suppressive tumor microenvironment and limitations in anti-tumor efficacy. The application of engineered bacteria offers a novel strategy to enhance CAR T cell therapy by modulating the tumor microenvironment and boosting immune responses, potentially leading to improved therapeutic outcomes. This review synthesizes the current research advancements related to engineered bacteria-assisted CAR T cell therapy in gastrointestinal cancers, exploring its underlying mechanisms, clinical applications, and future developmental directions. |
| Author | Song, Xiao Liu, Junhong Zhang, Qingqing Zhou, Xuejiao |
| AuthorAffiliation | 1 Reproductive Medicine , Weifang People’s Hospital , Weifang , Shandong , China 3 The Third Department of Geriatrics , Weifang People’s Hospital , Weifang , Shandong , China 4 Hospital Preparation Center , Weifang People’s Hospital , Weifang , Shandong , China 2 Department of Gastroenterology , Weifang People’s Hospital , Weifang , Shandong , China |
| AuthorAffiliation_xml | – name: 4 Hospital Preparation Center , Weifang People’s Hospital , Weifang , Shandong , China – name: 2 Department of Gastroenterology , Weifang People’s Hospital , Weifang , Shandong , China – name: 1 Reproductive Medicine , Weifang People’s Hospital , Weifang , Shandong , China – name: 3 The Third Department of Geriatrics , Weifang People’s Hospital , Weifang , Shandong , China |
| Author_xml | – sequence: 1 givenname: Qingqing surname: Zhang fullname: Zhang, Qingqing – sequence: 2 givenname: Xiao surname: Song fullname: Song, Xiao – sequence: 3 givenname: Junhong surname: Liu fullname: Liu, Junhong – sequence: 4 givenname: Xuejiao surname: Zhou fullname: Zhou, Xuejiao |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40297102$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkU1rXCEUhqWk5KtZd1dcdnMnft57XZUwpE0g0FJS6E7Ue5wY7uhUnUD-fUxmGpKNyvHlOZzznKCDmCIg9JmSBeejOk95wQiTCypHOsr-AzqmaiCdlHI4ePM-Qiel3BMyECLlIToShKmBEnaM_v7KqWzA1YKTxxBXIQJkmLA1rkIOpjOlhFJbZXnxG9_iJcwzrneQzeYRh4hXptScQqxQaohmxs5EB7l8Qh-9mQuc7e9T9Of75e3yqrv5-eN6eXHTOUH72hlrhAc3UqfU6PrejcRZZkZwfTuJtMoDHyzlygrgigtmB6DckEkKRZjnp-h6x52SudebHNYmP-pkgn4ppLzSJtfgZtADs8IqJbz3SjgPipPeiomMXFDlmG2sbzvWZmvXMDmINZv5HfT9Twx3epUeNGWEi4HxRvi6J-T0b9tWotehuLYyEyFti-ZU9T2V_aBa9MvbZq9d_rtpgfNdwDVFJYN_jVCin-234fSzfb23z58A05GjLw |
| Cites_doi | 10.1080/2162402X.2017.1284722 10.1038/s41551-024-01191-w 10.1002/bit.27596 10.1538/expanim.16-0033 10.1016/j.jcmgh.2023.07.001 10.21203/rs.3.rs-4031911/v1 10.3389/fimmu.2024.1353787 10.1038/nrd.2017.196 10.1038/s41551-022-00875-5 10.1590/1414-431x2024e13640 10.1142/S0192415X21500270 10.1021/acsnano.2c07607 10.1158/1078-0432.CCR-24-1853 10.1002/smll.202007494 10.1038/s41467-023-39224-8 10.1038/srep00436 10.1158/2159-8290.CD-23-1199 10.1093/annonc/mdz448 10.1136/jitc-2024-009960 10.18632/oncotarget.27769 10.1038/s41420-023-01626-4 10.1158/2326-6066.CIR-21-0515 10.1016/j.prp.2019.152687 10.1155/2016/5678702 10.1186/s12964-016-0160-z 10.1158/2159-8290.CD-20-1661 10.1016/j.xcrm.2023.101043 10.1007/s00262-022-03193-6 10.1186/s12929-022-00841-y 10.1136/gutjnl-2024-333227 10.1186/s13045-019-0813-7 10.1021/acsnano.4c15237 10.1016/j.mtbio.2023.100615 10.1155/jimr/5845167 10.1016/j.molcel.2014.03.040 10.1126/science.add7034 10.1126/science.add9667 10.1038/s41467-020-17011-z 10.18632/oncotarget.13217 10.3389/fimmu.2021.705999 10.1038/s41596-023-00927-3 10.1186/s12951-024-02793-x 10.1021/acsmaterialslett.3c00749 10.1038/s41368-024-00282-3 10.1021/acsnano.4c13320 10.3390/vaccines9121497 10.1016/j.biopha.2023.115740 10.1016/j.ccell.2023.01.009 10.1038/s41591-024-03037-z 10.3390/cells8060599 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Zhang, Song, Liu and Zhou. Copyright © 2025 Zhang, Song, Liu and Zhou. 2025 Zhang, Song, Liu and Zhou |
| Copyright_xml | – notice: Copyright © 2025 Zhang, Song, Liu and Zhou. – notice: Copyright © 2025 Zhang, Song, Liu and Zhou. 2025 Zhang, Song, Liu and Zhou |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/or.2025.1581856 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Zhang et al |
| EISSN | 1970-5557 |
| ExternalDocumentID | oai_doaj_org_article_72b4b994fff94cfe9306b4d083419c2b PMC12034723 40297102 10_3389_or_2025_1581856 |
| Genre | Journal Article Review |
| GroupedDBID | --- .86 123 29N 4.4 53G 5VS 67V 67Z 6NX 8TC 9T4 AAYXX ABDBF ACUHS ADBBV AFBBN AFKRA AHBYD ALMA_UNASSIGNED_HOLDINGS AOIJS BA0 BCNDV BENPR CAG CITATION CS3 EBD EBS GROUPED_DOAJ GXS HG5 HG6 HYE IZQ I~X KPH KQ8 N9A O9I OAM OK1 PGMZT PIMPY QOS R9I RNS RPM RPX RSV S1Z S27 SDH SMD SOJ T13 TSK U2A WJK WK8 -Y2 0R~ 2JY 2VQ AAIAL AANXM AAYZH ABFSG ACOMO ACSTC ADRAZ ADRFC AEZWR AFHIU AFLOW AGJBK AHSBF AHWEU AIXLP AMKLP CCPQU COF EJD EN4 H13 HZ~ IPNFZ KOV M48 NPM O9- PHGZM PHGZT RIG ROL 7X8 5PM |
| ID | FETCH-LOGICAL-c416t-aba4fec81c998c66c80cb2a8ec62a805b9fe37b139b4e39342b7e13a0d54902f3 |
| IEDL.DBID | DOA |
| ISSN | 1970-5557 1970-5565 |
| IngestDate | Wed Aug 27 01:13:15 EDT 2025 Thu Aug 21 18:26:40 EDT 2025 Tue Apr 29 20:10:06 EDT 2025 Mon Jul 21 05:26:35 EDT 2025 Tue Jul 01 05:10:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | gastrointestinal cancers CAR T cell therapy tumor microenvironment engineered bacteria immunotherapy |
| Language | English |
| License | Copyright © 2025 Zhang, Song, Liu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c416t-aba4fec81c998c66c80cb2a8ec62a805b9fe37b139b4e39342b7e13a0d54902f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Mauro Cives, University of Bari Aldo Moro, Italy Eleonora Pelle, Moffitt Cancer Center, United States Reviewed by: Barbara Mandriani, G. Pascale National Cancer Institute Foundation (IRCCS), Italy |
| OpenAccessLink | https://doaj.org/article/72b4b994fff94cfe9306b4d083419c2b |
| PMID | 40297102 |
| PQID | 3196615679 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_72b4b994fff94cfe9306b4d083419c2b pubmedcentral_primary_oai_pubmedcentral_nih_gov_12034723 proquest_miscellaneous_3196615679 pubmed_primary_40297102 crossref_primary_10_3389_or_2025_1581856 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-04-14 |
| PublicationDateYYYYMMDD | 2025-04-14 |
| PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Oncology reviews |
| PublicationTitleAlternate | Oncol Rev |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Tian (B37) 2022; 71 Zhang (B17) 2025; 2025 Qi (B14) 2024; 12 Gelsinger (B22) 2024; 19 Huang (B9) 2023; 16 Zhang (B26) 2016; 7 Han (B48) 2019; 12 Qi (B15) 2024; 30 Xia (B19) 2025; 19 Budimir (B46) 2022; 10 Lotter (B42) 2024; 14 Xiao (B47) 2024; 22 Romee (B21) 2024 Vincent (B7) 2023; 382 Murakami (B30) 2019; 8 Barrett (B16) 2024; 30 Tang (B34) 2023; 20 Lin (B18) 2019; 30 Li (B13) 2024; 57 Zhu (B24) 2025; 19 Yu (B32) 2012; 2 Jiang (B41) 2023; 17 Wang (B20) 2024; 16 Mullard (B4) 2017; 16 Jin (B45) 2023; 4 Nguyen (B25) 2023; 14 Kazmierczak (B31) 2020; 11 Catakovic (B5) 2017; 15 Wang (B12) 2021; 49 Jin (B6) 2022; 6 Liu (B29) 2016; 65 Danpanichkul (B1) 2025; 74 Arner (B10) 2023; 41 Zhou (B35) 2023; 168 Cai (B50) 2014; 54 Gurbatri (B8) 2022; 378 Wei (B3) 2017; 6 Chen (B33) 2021; 17 Nicolini (B44) 2024; 15 Huang (B11) 2019; 215 Gupta (B49) 2021; 9 Zhang (B23) 2023; 5 Wang (B27) 2016; 2016 Liang (B28) 2021; 118 Wang (B2) 2021; 12 Evgin (B39) 2020; 11 Fang (B38) 2023; 9 Wang (B40) 2024; 8 Alizadeh (B43) 2021; 11 Kung (B36) 2022; 29 |
| References_xml | – volume: 6 start-page: e1284722 year: 2017 ident: B3 article-title: PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells publication-title: OncoImmunology doi: 10.1080/2162402X.2017.1284722 – volume: 8 start-page: 561 year: 2024 ident: B40 article-title: Oncolytic mineralized bacteria as potent locally administered immunotherapeutics publication-title: Nat Biomed Eng doi: 10.1038/s41551-024-01191-w – volume: 118 start-page: 513 year: 2021 ident: B28 article-title: New technologies in developing recombinant-attenuated bacteria for cancer therapy publication-title: Biotechnol Bioeng doi: 10.1002/bit.27596 – volume: 65 start-page: 413 year: 2016 ident: B29 article-title: Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer publication-title: Exp Anim doi: 10.1538/expanim.16-0033 – volume: 16 start-page: 503 year: 2023 ident: B9 article-title: The origin, differentiation, and functions of cancer-associated fibroblasts in gastrointestinal cancer publication-title: Cell Mol Gastroenterol Hepatol doi: 10.1016/j.jcmgh.2023.07.001 – year: 2024 ident: B21 article-title: Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapy publication-title: Res Sq doi: 10.21203/rs.3.rs-4031911/v1 – volume: 15 start-page: 1353787 year: 2024 ident: B44 article-title: Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy publication-title: Front Immunol doi: 10.3389/fimmu.2024.1353787 – volume: 16 start-page: 669 year: 2017 ident: B4 article-title: FDA approves first CAR T therapy publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2017.196 – volume: 6 start-page: 830 year: 2022 ident: B6 article-title: CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers publication-title: Nat Biomed Eng doi: 10.1038/s41551-022-00875-5 – volume: 57 start-page: e13640 year: 2024 ident: B13 article-title: CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions publication-title: Braz J Med Biol Res doi: 10.1590/1414-431x2024e13640 – volume: 49 start-page: 609 year: 2021 ident: B12 article-title: Gut microbiota in tumor microenvironment: a critical regulator in cancer initiation and development as potential targets for Chinese medicine publication-title: Am J Chin Med doi: 10.1142/S0192415X21500270 – volume: 17 start-page: 843 year: 2023 ident: B41 article-title: Harnessing engineered immune cells and bacteria as drug carriers for cancer immunotherapy publication-title: ACS Nano doi: 10.1021/acsnano.2c07607 – volume: 30 start-page: 5413 year: 2024 ident: B16 article-title: Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-24-1853 – volume: 17 start-page: 2007494 year: 2021 ident: B33 article-title: Nanoengineered CAR‐T biohybrids for solid tumor immunotherapy with microenvironment photothermal‐remodeling strategy publication-title: Small doi: 10.1002/smll.202007494 – volume: 14 start-page: 3553 year: 2023 ident: B25 article-title: Bioengineering of bacteria for cancer immunotherapy publication-title: Nat Commun doi: 10.1038/s41467-023-39224-8 – volume: 2 start-page: 436 year: 2012 ident: B32 article-title: Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain publication-title: Sci Rep doi: 10.1038/srep00436 – volume: 14 start-page: 711 year: 2024 ident: B42 article-title: Artificial intelligence in oncology: current landscape, challenges, and future directions publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-23-1199 – volume: 30 start-page: xi12 year: 2019 ident: B18 article-title: Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdz448 – volume: 12 start-page: e009960 year: 2024 ident: B14 article-title: Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells publication-title: J Immunother Cancer doi: 10.1136/jitc-2024-009960 – volume: 11 start-page: 3943 year: 2020 ident: B31 article-title: Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model publication-title: Oncotarget doi: 10.18632/oncotarget.27769 – volume: 9 start-page: 328 year: 2023 ident: B38 article-title: Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors publication-title: Cell Death Discov doi: 10.1038/s41420-023-01626-4 – volume: 10 start-page: 146 year: 2022 ident: B46 article-title: Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-21-0515 – volume: 215 start-page: 152687 year: 2019 ident: B11 article-title: Hypoxia and lncRNAs in gastrointestinal cancers publication-title: Pathol - Res Pract doi: 10.1016/j.prp.2019.152687 – volume: 2016 start-page: 1 year: 2016 ident: B27 article-title: Strains, mechanism, and perspective: salmonella-based cancer therapy publication-title: Int J Microbiol doi: 10.1155/2016/5678702 – volume: 15 start-page: 1 year: 2017 ident: B5 article-title: T cell exhaustion: from pathophysiological basics to tumor immunotherapy publication-title: Cell Commun Signal doi: 10.1186/s12964-016-0160-z – volume: 11 start-page: 2248 year: 2021 ident: B43 article-title: IFNγ is critical for CAR T cell–mediated myeloid activation and induction of endogenous immunity publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-1661 – volume: 4 start-page: 101043 year: 2023 ident: B45 article-title: Engineer a double team of short-lived and glucose-sensing bacteria for cancer eradication publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2023.101043 – volume: 71 start-page: 2663 year: 2022 ident: B37 article-title: CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-022-03193-6 – volume: 29 start-page: 57 year: 2022 ident: B36 article-title: Localization of Salmonella and albumin-IL-2 to the tumor microenvironment augments anticancer T cell immunity publication-title: J Biomed Sci doi: 10.1186/s12929-022-00841-y – volume: 74 start-page: 26 year: 2025 ident: B1 article-title: Epidemiology of gastrointestinal cancers: a systematic analysis from the global burden of disease study 2021 publication-title: Gut doi: 10.1136/gutjnl-2024-333227 – volume: 12 start-page: 128 year: 2019 ident: B48 article-title: Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy publication-title: J Hematol Oncol doi: 10.1186/s13045-019-0813-7 – volume: 19 start-page: 5077 year: 2025 ident: B24 article-title: Innovative applications of bacteria and their derivatives in targeted tumor therapy publication-title: ACS Nano doi: 10.1021/acsnano.4c15237 – volume: 20 start-page: 100615 year: 2023 ident: B34 article-title: TGF-β blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells publication-title: Mater Today Bio doi: 10.1016/j.mtbio.2023.100615 – volume: 2025 start-page: 5845167 year: 2025 ident: B17 article-title: Advancements and future directions of dual‐target chimeric antigen receptor T‐cell therapy in preclinical and clinical studies publication-title: J Immunol Res doi: 10.1155/jimr/5845167 – volume: 54 start-page: 289 year: 2014 ident: B50 article-title: The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling publication-title: Mol Cell doi: 10.1016/j.molcel.2014.03.040 – volume: 382 start-page: 211 year: 2023 ident: B7 article-title: Probiotic-guided CAR-T cells for solid tumor targeting publication-title: Science doi: 10.1126/science.add7034 – volume: 378 start-page: 858 year: 2022 ident: B8 article-title: Engineering bacteria as interactive cancer therapies publication-title: Science doi: 10.1126/science.add9667 – volume: 11 start-page: 3187 year: 2020 ident: B39 article-title: Oncolytic virus-derived type I interferon restricts CAR T cell therapy publication-title: Nat Commun doi: 10.1038/s41467-020-17011-z – volume: 7 start-page: 81187 year: 2016 ident: B26 article-title: The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009 publication-title: Oncotarget doi: 10.18632/oncotarget.13217 – volume: 12 start-page: 705999 year: 2021 ident: B2 article-title: Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications publication-title: Front Immunol doi: 10.3389/fimmu.2021.705999 – volume: 19 start-page: 752 year: 2024 ident: B22 article-title: Bacterial genome engineering using CRISPR-associated transposases publication-title: Nat Protoc doi: 10.1038/s41596-023-00927-3 – volume: 22 start-page: 536 year: 2024 ident: B47 article-title: The application of bacteria-nanomaterial hybrids in antitumor therapy publication-title: J Nanobiotechnol doi: 10.1186/s12951-024-02793-x – volume: 5 start-page: 2785 year: 2023 ident: B23 article-title: An engineered bacterium-based lactate bioconsumer for regulating immunosuppressive tumor microenvironment to potentiate antitumor immunity publication-title: ACS Mater Lett doi: 10.1021/acsmaterialslett.3c00749 – volume: 16 start-page: 24 year: 2024 ident: B20 article-title: Promising dawn in tumor microenvironment therapy: engineering oral bacteria publication-title: Int J Oral Sci doi: 10.1038/s41368-024-00282-3 – volume: 19 start-page: 5376 year: 2025 ident: B19 article-title: Orthogonally engineered bacteria capture metabolically labeled tumor antigens to improve the systemic immune response in irradiated tumors publication-title: ACS Nano doi: 10.1021/acsnano.4c13320 – volume: 9 start-page: 1497 year: 2021 ident: B49 article-title: Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy publication-title: Vaccines doi: 10.3390/vaccines9121497 – volume: 168 start-page: 115740 year: 2023 ident: B35 article-title: Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment publication-title: Biomed and Pharmacother doi: 10.1016/j.biopha.2023.115740 – volume: 41 start-page: 421 year: 2023 ident: B10 article-title: Metabolic programming and immune suppression in the tumor microenvironment publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.01.009 – volume: 30 start-page: 2224 year: 2024 ident: B15 article-title: Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results publication-title: Nat Med doi: 10.1038/s41591-024-03037-z – volume: 8 start-page: 599 year: 2019 ident: B30 article-title: Efficacy of tumor-targeting Salmonella typhimurium A1-R against malignancies in patient-derived orthotopic xenograft (PDOX) murine models publication-title: Cells doi: 10.3390/cells8060599 |
| SSID | ssj0070055 |
| Score | 2.3092794 |
| SecondaryResourceType | review_article |
| Snippet | The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1581856 |
| SubjectTerms | CAR T cell therapy engineered bacteria gastrointestinal cancers immunotherapy Oncology Reviews tumor microenvironment |
| Title | Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40297102 https://www.proquest.com/docview/3196615679 https://pubmed.ncbi.nlm.nih.gov/PMC12034723 https://doaj.org/article/72b4b994fff94cfe9306b4d083419c2b |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlh9JLadqmcdIWFXroxYklj23pmC4NoZBSSgJ7E_pMA8EO3s2h_74zljdkSyCXXnywBRLvyZo3SPPE2GcrfFBWQdlo70uAkEpda1emzinVUK1kRdXI5z_as0v4vmyWD676ojNh2R44A3fcSQdOa0gpafApatS4DgIqBxDaS0erL8a8TTKV1-COrKWykQ-mYPp4IOdP2RyJhuJTuxWDJqv-x_Tlv8ckH8Sd01fs5SwY-Uke6C57FvvX7Pn5vCX-hi1_jsNULrniQ-JxtheMgbvsw2xLlMfEZeCLk1_8gi_izQ3PZVd_-HXPr-xqPQ5kG4F_O3XlaSKMq7fs8vTbxeKsnK9LKD2qqnVpnYUUvRIeUyjftl5V3kmrom_xWTVOp1h3DiWfg1jrGqTroqhtFTBHrGSq99hOP_Rxn3FMixsRVKMrW4HD8CVD65LufAptAi8K9mUDoLnNrhgGswnC2gyjIazNjHXBvhLA983Iznp6gSSbmWTzFMkF-7Shx-D0pz0N28fhbmVoBUFR1na6YO8yXfddAV3MhQKqYGqLyK2xbH_pr39PFttCVjV0sj74H6M_ZC8IEdqDEvCe7azHu_gBpczafZxm7V-n0_MX |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prospects+of+engineered+bacteria-assisted+CAR+T+Cell+therapy+in+gastrointestinal+cancers&rft.jtitle=Oncology+reviews&rft.au=Zhang%2C+Qingqing&rft.au=Song%2C+Xiao&rft.au=Liu%2C+Junhong&rft.au=Zhou%2C+Xuejiao&rft.date=2025-04-14&rft.issn=1970-5565&rft.volume=19&rft.spage=1581856&rft_id=info:doi/10.3389%2For.2025.1581856&rft_id=info%3Apmid%2F40297102&rft.externalDocID=40297102 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1970-5557&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1970-5557&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1970-5557&client=summon |